The bioavailability of phenytoin.
The bioavailability of three commercial products of phenytoin (Epanutin, sodium salt; Phenhydan, calcium salt; Zentropil, free acid) was studied relative to a standard solution of sodium phenytoin. Each preparation was given for 14 days in a daily dose of 300 mg according to a cross over design. The three brands tested were equivalent as to their bioavailability with respect to plasma concentrations during one dosing interval, the area under the plasma level time curve, the time of peak plasma concentration, and the urinary excretion of the primary metabolite. Therefore, these phenytoin brands are bioequivalent and exchangeable for antiepileptic treatment. The standard solution of sodium phenytoin had a higher bioavailability as compared to the commercial products.
D000328:Adult; D001682:Biological Availability; D001711:Biotransformation; D005260:Female; D006801:Humans; D007700:Kinetics; D008297:Male; D010672:Phenytoin / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism*; D013997:Time Factors
D010672:Phenytoin